Travere Therapeutics, INC Form 4 insider transactions

William E. Rote, Chief Research Officer of Travere Therapeutics, Inc., sold 209,048 shares of common stock on September 15, 2026.

Peter Heerma, EVP, CHIEF COMMERCIAL OFFICER of Travere Therapeutics, Inc., sold 283,189 shares of common stock on September 15, 2026.

Jula Inrig, EVP, Head of R&D & CMO of Travere Therapeutics, Inc., sold 44,674 shares of common stock on September 15, 2026.

Elizabeth E Reed, Chief Legal Officer and GC of Travere Therapeutics, Inc., sold 37,500 shares of common stock on September 15, 2026.

Eric M Dube, CHIEF EXECUTIVE OFFICER and a Director of Travere Therapeutics, Inc., sold 400,000 shares of common stock on September 15, 2026.

Christopher R. Cline, CHIEF FINANCIAL OFFICER of Travere Therapeutics, Inc., sold 50,508 shares of common stock on September 15, 2026.

Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER of Travere Therapeutics, Inc., sold 5,375 shares of common stock on September 15, 2026.

Jeffrey A Meckler, a Director of Travere Therapeutics, Inc., sold 20,000 shares of common stock on September 10, 2026.

Gary A Lyons, a Director of Travere Therapeutics, Inc., sold 10,000 shares of common stock on August 17, 2026.

Travere Therapeutics Director Timothy Coughlin exercised 10,000 stock options and sold the resulting shares via a 10b5-1 plan.

Director Roy D. Baynes exercised 4,500 stock options and sold the resulting shares of Travere Therapeutics, Inc. (TVTX).

Ruth Williams Brinkley, a Director at Travere Therapeutics, Inc., was granted 4,000 shares of common stock and 12,000 stock options as part of the company's non-employee director compensation program.

Director Ron Squarer acquired 4,000 shares of common stock in Travere Therapeutics, Inc. through an automatic equity grant.

Travere Therapeutics reports a director, Sandra Poole, received an automatic equity grant of 4,000 common stock shares and a stock option.

Director John Orwin acquired 4,000 shares of common stock and was granted stock options for 12,000 shares in Travere Therapeutics, Inc.

Travere Therapeutics, Inc. reports an automatic equity grant to Director Jeffrey A. Meckler under the company's incentive plan.

Director Gary Lyons acquired 4,000 shares of common stock and was granted 12,000 stock options in Travere Therapeutics, Inc. on May 19, 2026.

Travere Therapeutics Director Timothy Coughlin acquired 4,000 shares of common stock through an automatic equity grant.

Suzanne Louise Bruhn, a Director at Travere Therapeutics, Inc., was granted 4,000 shares of common stock and 12,000 stock options as part of the company's non-employee director compensation program.

Travere Therapeutics, Inc. reports an automatic equity grant to Director Roy D. Baynes under the company's incentive plan.

Travere Therapeutics director Roy D. Baynes exercised 4,500 stock options and subsequently sold the shares under a 10b5-1 plan.

Director Jeffrey Meckler exercised 8,000 stock options and sold the resulting shares of Travere Therapeutics, Inc. under a Rule 10b5-1 trading plan.

Chief Research Officer William E. Rote reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Chief Legal Officer Elizabeth E. Reed reported the exercise of stock options and the vesting of performance-based restricted stock units.

Chief Medical Officer Jula Inrig exercised options and sold shares of Travere Therapeutics following performance-based vesting.

Chief Commercial Officer Peter Heerma acquired 4,250 shares via PSU vesting and sold 2,174 shares to cover tax obligations.

Travere Therapeutics CEO Eric Dube sold 22,500 shares following the vesting of performance-based restricted stock units.

Travere Therapeutics CFO Christopher R. Cline reported the vesting of performance-based restricted stock units and subsequent sell-to-cover tax transactions.

Director Roy D. Baynes of Travere Therapeutics, Inc. sold 9,750 shares of common stock underlying vested stock options on May 1, 2026, as part of a pre-arranged 10b5-1 trading plan.

Travere Therapeutics Chief Research Officer William E. Rote sold 9,100 shares of common stock for $39.09 per share, totaling $355,719, as part of a pre-arranged trading plan.